Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / RBGPF - Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits | Benzinga


RBGPF - Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits | Benzinga

Abbott Laboratories (NYSE:ABT) is set to face trial on Monday over allegations that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease known as necrotizing enterocolitis (NEC).

This is the second trial out of hundreds of similar lawsuits in the U.S.

Also Read: Class Action Against Abbott’s Glucerna Products Proceeds in Federal Court.

Lawyers for Abbott and Illinois resident Margo Gill will make their opening statements to jurors in St. Louis, Missouri, with the trial expected to last most of the month.

Gill claims her premature infant developed NEC after being fed Abbott’s products for premature babies, which causes the death of bowel tissue, primarily affects newborns, and has a fatality rate of 15% ...

Full story available on Benzinga.com

Stock Information

Company Name: Reckitt Benckiser Group Plc
Stock Symbol: RBGPF
Market: OTC
Website: reckitt.com

Menu

RBGPF RBGPF Quote RBGPF Short RBGPF News RBGPF Articles RBGPF Message Board
Get RBGPF Alerts

News, Short Squeeze, Breakout and More Instantly...